ArticleNature medicine2024

Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses.

Ronan J Kelly et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.